Endo settles New Yor opioid case
The plaintiffs in the foregoing cases asserted various claims relating to the defendants' marketing and sale of prescription opioid medications and/or alleged failures to take adequate steps to identify and report suspicious orders. A jury trial on liability has been ongoing since June 2021.
As a result of the settlement, Endo's subsidiaries have been severed from the trial. The settlement fully and finally resolves all of the asserted claims in exchange for a total payment of $50 million. The settlement includes no admission of wrongdoing, fault or liability of any kind by Endo or its subsidiaries, and the settlement value should not be extrapolated to any other opioid-related cases or claims. ■